|
N
|
4274
|
922
|
652
|
554
|
357
|
227
|
106
|
98
|
49
|
1309
|
|
Sex (n, %)
|
|
Male
|
2103 (49.2)
|
307 (33.3)
|
390 (59.8)
|
329 (59.4)
|
195 (54.6)
|
122 (53.7)
|
64 (60.4)
|
43 (43.9)
|
28 (57.1)
|
625 (47.8)
|
|
Female
|
2171 (50.8)
|
615 (66.7)
|
262 (40.2)
|
225 (40.6)
|
162 (45.4)
|
105 (46.3)
|
42 (39.6)
|
55 (56.1)
|
21 (42.9)
|
684 (52.2)
|
|
Race
|
|
White
|
3729 (87.3)
|
783 (84.9)
|
576 (88.3)
|
499 (90.1)
|
309 (86.6)
|
203 (89.4)
|
96 (90.6)
|
82 (83.7)
|
43 (87.8)
|
1138 (86.9)
|
|
Black
|
337 (7.9)
|
106 (11.5)
|
46 (7.1)
|
23 (4.2)
|
21 (5.9)
|
–
|
–
|
–
|
–
|
106 (8.1)
|
|
Other
|
197 (4.6)
|
31 (3.4)
|
26 (4.0)
|
32 (5.8)
|
25 (7.0)
|
–
|
–
|
–
|
–
|
63 (4.8)
|
|
Age at advanced diagnosis
|
|
Mean (SD)
|
77.8 (7.3)
|
76.8 (7.2)
|
79.4 (7.2)
|
77.5 (7.1)
|
78.2 (7.5)
|
77.8 (7.1)
|
77.7 (7.6)
|
76.8 (7.3)
|
74.1 (6.5)
|
78.0 (7.4)
|
|
Median
|
77.4
|
76.1
|
79.7
|
76.6
|
77.9
|
77.8
|
77.3
|
76.6
|
73.5
|
77.5
|
|
Min, Max
|
65.0, 104.1
|
65.0, 102.9
|
65.1, 99.3
|
65.1, 96.8
|
65.6, 101.8
|
65.7, 97.4
|
65.5, 95.9
|
65.3, 95.3
|
65.7, 91.0
|
65.1, 104.1
|
|
Pre-index date Charlson Comorbidity Index (CCI) scorea
|
|
Mean (SD)
|
2.8 (2.3)
|
2.5 (2.2)
|
2.8 (2.4)
|
2.8 (2.3)
|
2.9 (2.7)
|
2.8 (2.2)
|
2.8 (2.3)
|
2.6 (2.1)
|
3.0 (2.3)
|
2.8 (2.4)
|
|
Median
|
2.0
|
2.0
|
2.0
|
2.0
|
2.0
|
2.0
|
2.0
|
2.0
|
2.0
|
2.0
|
|
Min, Max
|
0.0, 15.0
|
0.0, 14.0
|
0.0, 15.0
|
0.0, 12.0
|
0.0, 12.0
|
0.0, 11.0
|
0.0, 10.0
|
0.0, 9.0
|
0.0, 8.0
|
0.0, 15.0
|
|
Stage of disease at initial diagnosis of STS (n, %)
|
|
Localized
|
1731 (40.5)
|
345 (37.4)
|
379 (58.1)
|
260 (46.9)
|
150 (42.0)
|
121 (53.3)
|
36 (34.0)
|
25 (25.5)
|
18 (36.7)
|
397 (30.3)
|
|
Regional—direct extension only
|
938 (22.0)
|
200 (21.7)
|
135 (20.7)
|
177 (32.0)
|
62 (17.4)
|
59 (26.0)
|
32 (30.2)
|
14 (14.3)
|
11 (22.5)
|
248 (19.0)
|
|
Regional—lymph nodes involved only
|
29 (0.7)
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
0 (0.0)
|
–
|
|
Regional—direct extension and lymph nodes
|
37 (0.9)
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
0 (0.0)
|
–
|
|
Distant
|
1539 (36.0)
|
363 (39.4)
|
133 (20.4)
|
114 (20.6)
|
138 (38.7)
|
45 (19.8)
|
36 (34.0)
|
53 (54.1)
|
20 (40.8)
|
637 (48.7)
|
|
Grade of cancer at time of initial diagnosis of STS (n, %)
|
|
Well or moderately differentiated (grade 1 or 2)
|
646 (15.1)
|
152 (16.5)
|
36 (5.5)
|
239 (43.1)
|
40 (11.2)
|
50 (22.0)
|
–
|
–
|
–
|
116 (8.9)
|
|
Poorly differentiated (grade 3)
|
908 (21.2)
|
192 (20.8)
|
151 (23.2)
|
101 (18.2)
|
81 (22.7)
|
35 (15.4)
|
–
|
–
|
16 (32.7)
|
294 (22.5)
|
|
Undifferentiated (grade 4)
|
1310 (30.7)
|
250 (27.1)
|
228 (35.0)
|
129 (23.3)
|
61 (17.1)
|
63 (27.8)
|
28 (26.4)
|
34 (34.7)
|
–
|
510 (39.0)
|
|
Unknown
|
1410 (33.0)
|
328 (35.6)
|
237 (36.4)
|
85 (15.3)
|
175 (49.0)
|
79 (34.8)
|
54 (50.9)
|
39 (39.8)
|
24 (49.0)
|
389 (29.7)
|
|
Total follow-up time (years)b
|
|
Mean (SD)
|
1.7 (2.4)
|
1.8 (2.2)
|
2.0 (2.8)
|
2.6 (2.8)
|
1.1 (1.7)
|
2.5 (2.7)
|
1.4 (2.1)
|
0.8 (1.5)
|
1.4 (1.8)
|
1.3 (2.0)
|
|
Median
|
0.7
|
1.0
|
0.8
|
1.5
|
0.5
|
1.6
|
0.5
|
0.3
|
0.6
|
0.5
|
|
Min, Max
|
0.0, 12.8
|
0.0, 12.2
|
0.0, 12.3
|
0.0, 12.3
|
0.0, 12.5
|
0.0, 12.5
|
0.0, 9.9
|
0.0, 9.8
|
0.0, 8.8
|
0.0, 12.8
|
